BCMU
BMRN icon

BlueCrest Capital Management (UK)’s BioMarin Pharmaceuticals BMRN Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2.7M Hold
37,400
– – 0.1% 200
2014
Q2 		$2.33M Hold
37,400
– – 0.08% 206
2014
Q1 		$2.55M Buy
37,400
+21,900
+141% +$1.61M 0.14% 176
2013
Q4 		$1.09M Buy
+15,500
New +$1.05M 0.09% 206

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlueCrest Capital Management (UK)'s BMRN Position: Q3 2014 in Review

BlueCrest Capital Management (UK) held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2014 at 37,400 shares worth $2.7M. The position accounts for 0.1% of the portfolio, ranked #200.

BlueCrest Capital Management (UK) first reported a position in BMRN in Q4 2013 and has held it in 4 quarters since. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

  • BlueCrest Capital Management (UK) held 37,400 shares of BioMarin Pharmaceuticals worth $2.7M as of Q3 2014.
  • BlueCrest Capital Management (UK) left its BioMarin Pharmaceuticals share count unchanged in Q3 2014.
  • BioMarin Pharmaceuticals made up 0.1% of BlueCrest Capital Management (UK)'s portfolio in Q3 2014, its #200 holding.
  • BlueCrest Capital Management (UK) first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 4 quarters since.
  • 316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q3 2014, filed 13 Nov 2014.